Ongoing Clinical Trials for Urethral Stenosis
There is currently 1 ongoing clinical trial investigating new treatment approaches for urethral stenosis, a condition characterized by narrowing of the urethra that can cause difficulties with urination. This trial is exploring an innovative cell-based therapy using a patient’s own fat tissue cells to improve outcomes following standard surgical procedures.
Clinical trial locations
Study on the Safety of Autologous Adipose Tissue-Derived Stromal Vascular Fraction Cells for Patients with Recurrent Urethral Stricture
This clinical trial is being conducted in France and focuses on testing a novel treatment approach for patients experiencing recurrent narrowing of the urethra, specifically in a portion called the bulbar urethra.
Main inclusion criteria:
- Male patients between 18 and 85 years of age
- Diagnosed with bulbar urethral narrowing that is 3 cm or less in length
- The narrowing must be severe enough that a standard medical instrument cannot pass through, and patients must experience bothersome symptoms or complications such as infections or difficulty urinating
- Must have undergone at least one previous procedure called urethral dilatation or urethrotomy within the past 24 months
- Good general health status confirmed through medical history and physical examination
- Body Mass Index (BMI) greater than 18, ensuring adequate fat tissue is available for the procedure
- Ability to avoid medications that affect the immune system (corticoids or immunosuppressive drugs) for one month after treatment
Main exclusion criteria:
- Female patients are not eligible for this study
- Individuals outside the specified age range
- Patients with urethral conditions other than the specific type of narrowing being studied
- Individuals belonging to vulnerable populations requiring special protection or care
Focus and goal of the trial:
The primary purpose of this study is to evaluate the safety and tolerability of a new treatment that uses special cells harvested from a patient’s own fat tissue. These cells, called stromal vascular fraction (SVF) cells, are prepared as a suspension and injected under the skin as an additional treatment alongside endoscopic urethrotomy, which is the standard surgical procedure for treating urethral narrowing.
Participants will be monitored closely throughout the study to assess any side effects such as urethral bleeding, urinary infections, or pain. The study will also evaluate improvements in symptoms and quality of life using questionnaires and various tests including uroflowmetry to measure urine flow and ultrasound scans to check bladder emptying. Some participants may undergo MRI scans to evaluate changes in tissue structure.
The trial will follow patients for up to 24 months after the injection to monitor for recurrence of symptoms and to gather valuable information about whether this innovative cell-based therapy can help improve outcomes for patients with recurrent urethral narrowing.
Investigational treatment:
The study uses ADSVF (Autologous Adipose Tissue-Derived Stromal Vascular Fraction), a regenerative medicine therapy containing stem cells and growth factors extracted from the patient’s own fat tissue. These cells are believed to aid tissue repair and regeneration at the molecular level. The treatment is administered through subcutaneous injection as an add-on to the standard endoscopic urethrotomy procedure. This approach allows researchers to determine whether the cell therapy can enhance healing and reduce the likelihood of the narrowing returning.
Summary
Currently, there is one active clinical trial investigating new treatment options for urethral stenosis. This trial is taking place in France and represents an innovative approach to managing recurrent narrowing of the urethra by combining standard surgical treatment with regenerative cell therapy derived from patients’ own fat tissue.
The study focuses specifically on a particular type of urethral narrowing (bulbar urethral stenosis) that has recurred despite previous treatment. By using the patient’s own cells, the therapy aims to minimize rejection risks while potentially enhancing tissue healing and reducing recurrence rates.
Patients interested in participating should note that the trial has specific requirements regarding age, health status, body mass index, and previous treatment history. The study will provide important information about the safety profile of this regenerative medicine approach and may help guide future treatment options for individuals struggling with recurrent urethral narrowing.
